panbronchiolitis%20-%20diffuse
PANBRONCHIOLITIS - DIFFUSE
Diffuse panbronchiolitis is an inflammatory disease affecting the respiratory bronchioles.
It causes progressive suppurative and obstructive respiratory disease.
This is an idiopathic disease which is primarily found in Japan, Korea and China.
Predisposition to the disease may be genetically-related but environmental factors should also be considered.
Failure to treat diffuse panbronchiolitis can lead to development of bronchiectasis, progressive failure and death.

Pharmacotherapy

  • Macrolides should be started as soon as diagnosis is established

Macrolides

  • Eg Erythromycin,14 member-ringed macrolides (eg Clarithromycin, Roxithromycin), & the 15 member-ringed macrolide Azithromycin
  • Erythromycin is the 1st choice in treatment of diffuse panbronchiolitis (DPB)
    • Treatment duration is for at least 6 months
  • Other macrolides (Clarithromycin, Roxithromycin, Azithromycin) are used when Erythromycin is ineffective or not tolerated
  • Studies show better lung function (decreased dyspnea, opacities in HRCT) w/ Azithromycin use in patients w/ DPB

Actions:

  • Inhibit production of pro-inflammatory cytokines & formation of leukotriene B4
  • Block the formation of adhesion molecules required for migration of neutrophils

Effects:

  • Decreased inflammation of the airways, leading to improved pulmonary function & decreased infection
  • Erythromycin helps improve host defense & regulate bacterial activities
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 19 Jun 2016
Infants with persistent rhinitis have a higher abundance of Actinobacteria, especially Corynebacterium spp., in their nasal microbiome compared with healthy controls, according to a Singapore-based study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2016 held in Vienna, Austria.
29 Nov 2017
Lansoprazole, a widely available and commonly prescribed proton pump inhibitor (PPI), appears to reduce the incidence of tuberculosis disease, a recent study has found.
Gabriel Angelo Sembrano, 16 Sep 2014

“At present, there is a limited development of new antibiotics. There is also a fast development of resistance to antibiotics. There are pathogens no longer susceptible to all antibiotics, and many pathogens are no longer susceptible to most antibiotics,” said Dr. Andre Villanueva, chief of party of the USAID’s Innovations and Multisectoral Partnerships to Achieve Control of TB (IMPACT) Project at the recent Annual Convention of the Philippine Pharmacists’ Association in Davao City.

Pearl Toh, 31 May 2016
Synbiotic mixture of oligosaccharides and Bifidobacterium breve (B. breve) M-16V probiotic strain in infant formula restores gut colonisation by B. breve and supports healthy gut development in infants delivered by Caesarean-section (C-section), according to a study presented at the recent European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) annual meeting held in Athens, Greece.